Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott/Triangle To File Coactinon In 1999 Under $335 Mil. Co-Promotion

Executive Summary

Triangle Pharmaceuticals could file an NDA for its anti-HIV product Coactinon (emivirine) by year-end under a $335 mil. co-promotion agreement with Abbott announced June 3.

You may also be interested in...



Triangle Coviracil NDA Slated For September; Abbott Bows Out As Partner

Triangle Pharmaceuticals will file an NDA for Coviracil in September without a marketing partner following the reacquisition of rights to the nucleoside reverse transcriptase inhibitor from Abbott

Triangle Coviracil NDA Slated For September; Abbott Bows Out As Partner

Triangle Pharmaceuticals will file an NDA for Coviracil in September without a marketing partner following the reacquisition of rights to the nucleoside reverse transcriptase inhibitor from Abbott

Triangle Coviracil Study Completion Funded Via $100 Mil. Equity Facility

Triangle Pharmaceuticals' $100 mil. equity facility appears to be sufficient to finance the company until it completes clinical development of the HIV nucleoside analogue Coviracil (emtricitabine).

Related Content

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel